November 16, 2007
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director, President and Chief Executive Officer

News Release 10/23/2007
Cephalon Announces Positive Results from Its Pivotal Study of TREANDA® in Patientswith Non-Hodgkin's Lymphoma
Company on Target to File Second New Drug Application for TREANDA® by End of 2007

FRAZER, Pa., Oct. 23
Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a Phase 3
clinical trial of TREANDA® (bendamustine HCl) in patients with indolent
non-Hodgkin's lymphoma (NHL) whose cancer is no longer responsive to treatment
with rituximab. The study met its primary endpoints of overall response rate andmedian duration of response, while demonstrating a manageable tolerability profile.
According to the National Cancer Institute, an estimated 30,000 people in the UnitedStates will be diagnosed in 2007 with indolent NHL, a serious and slow growing cancerof the lymphatic system that is difficult to treat because patients are prone to relapse
after treatment.
The Phase 3, multicenter, single-arm study evaluated the efficacy and safety ofsingle-agent TREANDA® in 100 patients with relapsed, rituximab-refractory NHL. The
overall response rate, as assessed by an independent radiological committee, was 75%(p<0.0001) and the median duration of response was 40 weeks (or 9.2 months). The
overall response rate includes the percent of patients in the trial who had a complete,unconfirmed complete or partial response to treatment. The most common side effects
included nausea, fatigue, neutropenia, diarrhea and vomiting. The company anticipatesthat the results of this study will be released at the upcoming American Society ofHematology (ASH) annual meeting in December 2007.
"We are encouraged that these results replicate those seen in our Phase 2 study,
confirming the substantial efficacy in this difficult to treat population," said Dr. LesleyRussell, Executive Vice President, Worldwide Medical and Regulatory Operations.
"Based on these positive results, we are on track to file a New Drug Application in thefourth quarter for TREANDA® in patients with indolent NHL who have failed
treatment with rituximab."The protocol for the NHL pivotal trial received special protocol assessment (SPA)
approval from the U.S. Food and Drug Administration (FDA) in February 2006. The
SPA process allows for FDA evaluation and acceptance of a clinical trial protocol,including trial size, clinical endpoints and/or data analysis, which will be used as thebasis of an efficacy claim to support a New Drug Application (NDA).
In September 2007, Cephalon submitted an NDA requesting approval of TREANDA®
for the treatment of patients with chronic lymphocytic leukemia (CLL), for which theFDA has granted orphan drug status.

[Company Profile]
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals’ focus is on oncology/hematology and autoimmune disease
therapies. Established in March 2005 by Fuminori Yoshida, who previously served asboth Corporate Vice President of Amgen Inc. and president of Amgen Japan, SymBio
Pharmaceuticals’ underlying corporate philosophy is “delivering hope to patients inneed,” and the company aims to address unmet medical needs of patients in Japan bycultivating a mutually beneficial or symbiotic relationship among physicians, scientists,regulatory agencies, and investors. SymBio Pharmaceuticals core philosophy is thatprofitability and socially responsibility as a pharmaceutical enterprise can go hand inhand, and need not be mutually exclusive.
For further information, please contact:
Osamu Ogawa, Senior Corporate Officer, COO
SymBio Pharmaceuticals Limited
Tel: +81(0) 3 5472 1123
E-mail: Please send your inquiry through “INQUIRY” in our homepage
URL: http://www.symbiosis.co.jp